Home Stock Alerts


Lipocine Inc. (LPCN) Sank To A New Low After Failing To Win FDA Panel Backing
1/12/2018 7:10 AM

Lipocine Inc. (LPCN) announced after the close Wednesday that its New Drug Application for its oral testosterone product candidate TLANDO has failed to win support from an advisory committee to FDA.

Lipocine gapped open sharply lower Thursday, but traded in a range for the majority of the session. The stock closed down by 1.59 at $1.87 with volume at over a 7-month high. Lipocine plunged to a new low for the year.

Top Stories | Breaking News | Latest Headlines | Commodities | Forex | Stock Alerts | Entertainment | Economic News | Politics | Commentary

Copyright © 2018 RTTNews.